Published in BMJ Open on May 15, 2015
Pediatric Statin Administration: Navigating a Frontier with Limited Data. J Pediatr Pharmacol Ther (2016) 0.75
Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. J Am Soc Nephrol (2017) 0.75
Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis. PLoS One (2017) 0.75
Mechanisms and consequences of carbamoylation. Nat Rev Nephrol (2017) 0.75
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 2.51
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med (2001) 2.35
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J (2013) 1.74
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol (2008) 1.73
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis (2009) 1.68
The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis (2007) 1.67
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia (2010) 1.53
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2009) 1.52
Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant (1997) 1.29
Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med (2014) 1.11
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol (2013) 0.98
Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J (2011) 0.95
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med (2011) 0.94
How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol (2004) 0.84
Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. BMC Cardiovasc Disord (2014) 0.83
Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol (2013) 0.82
Statins in chronic kidney disease: cardiovascular risk and kidney function. Postgrad Med (2014) 0.81
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. J Intern Med (2009) 0.80
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke (2014) 0.79
Medical management of stable coronary atherosclerosis. Curr Atheroscler Rep (2013) 0.78
Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in coronary artery disease: A systematic review and meta-analysis. Int J Cardiol (2015) 0.82
The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. Clin Chim Acta (2015) 0.79
Adjunctive manual thrombus aspiration during ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.78
The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens. J Clin Pharmacol (2015) 0.76
Calcium channel blocker compared with angiotensin receptor blocker for patients with hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich) (2014) 0.76